Menu Search
Equities

Hologic Inc

0J5Q:LSE

Hologic Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jun 02 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics segment offers a range of diagnostics products, such as ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Its Breast Health segment offers a portfolio of solutions for breast cancer care, primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment offers a range of products, such as NovaSure Endometrial Ablation System, MyoSure Hysteroscopic Tissue Removal System and Fluent Fluid Management system as well as its Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment offers products such as the Horizon DXA, a dual energy x-ray system, and the Fluoroscan Insight FD mini C-arm.

  • Revenue in USD (TTM)4.06bn
  • Net income in USD753.00m
  • Incorporated1990
  • Employees6.94k
  • Location
    Hologic Inc250 Campus DriveMARLBOROUGH 1752United StatesUSA
  • Phone+1 (781) 999-7300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.hologic.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.